Legal & General Group
FBLG icon

Legal & General Group’s FibroBiologics FBLG Stock Holding History

Legal & General Group’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-141
Closed -$2.54K – 3561
2025
Q1 		$2.54K Hold
141
– – ﹤0.01% 3340
2024
Q4 		$5.63K Hold
141
– – ﹤0.01% 3329
2024
Q3 		$8.7K Hold
141
– – ﹤0.01% 3297
2024
Q2 		$14.1K Buy
+141
New +$26.9K ﹤0.01% 3169

Other funds holding FBLG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group's FBLG Position: Q2 2025 in Review

Legal & General Group sold out of FibroBiologics (FBLG) in Q2 2025, closing a stake of 141 shares — an estimated $2.54K sold.

Legal & General Group first reported a position in FBLG in Q2 2024 and held it in 4 quarters. The position peaked at $14.1K in Q2 2024. 57 funds tracked by Wall St. Rank hold FBLG as of Q2 2025.

  • Legal & General Group reported no remaining FibroBiologics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 141 FibroBiologics shares in Q2 2025, an estimated $2.54K.
  • Legal & General Group first reported a position in FibroBiologics in Q2 2024 and held it in 4 quarters.
  • Legal & General Group's FibroBiologics position peaked at $14.1K in Q2 2024.
  • 57 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.